SCHEMBL2092151

SCHEMBL2092151

COc1ccc(-n2cccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.60
KDM4E B2RXH2 3/20 0.60
ALDH1A1 P00352 3/20 0.60
MEN1 O00255 1/20 0.60
PKM P14618 1/20 0.60
BLM P54132 1/20 0.60
KMT2A Q03164 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.50
HSD17B10 Q99714 2/20 0.50
LMNA P02545 2/20 0.50
THRB P10828 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28455373 0.80 MGLL (0.57) MAPTKDM4EALDH1A1MEN1PKM
SCHEMBL2091295 0.77 MGLL (0.53) MAPTALDH1A1PKMCYP1A2CA1
SCHEMBL2092147 0.76 KDM4E (0.45) MAPTKDM4EALDH1A1MEN1PKM
SCHEMBL20201235 0.76 KDM4E (0.45) MAPTKDM4EALDH1A1MEN1PKM
SCHEMBL5104129 0.76 NQO1 (0.58) MAPTKDM4EALDH1A1MEN1PKM
SCHEMBL7013183 0.74 LTA4H (0.55) KDM4EMEN1PKMKMT2ACA1
SCHEMBL11417007 0.74 CYP1A2 (1.00) MAPTALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1670288 0.74 CYP1A2 (0.52) MAPTKDM4EALDH1A1MEN1PKM
SCHEMBL16720130 0.73 CHRNB2 (0.49) CYP1A2CYP2C9
SCHEMBL4722619 0.73 CYP1A2 (0.54) MAPTKDM4EALDH1A1MEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115141220-A Aza-BODIPY compound and application thereof in-vivo tracing of nanoparticles 复旦大学 2022-10-04 CN claimed
US-10591435-B2 Electropolymerization onto flexible substrates for electronic applications CORNELL UNIVERSITY (US) 2020-03-17 US claimed
CN-107434830-A Wide-distribution polypropylene catalyst component, preparation method and catalyst thereof 中国石油天然气股份有限公司 2017-12-05 CN claimed
US-20170023513-A1 ELECTROPOLYMERIZATION ONTO FLEXIBLE SUBSTRATES FOR ELECTRONIC APPLICATIONS CORNELL UNIVERSITY 2017-01-26 US claimed
CN-117377668-A Inhalant formulations of PGDH inhibitors and methods of use thereof 迈欧伏特治疗公司 2024-01-09 CN disclosed
US-20230167067-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES UNIV NORTH CAROLINA CHAPEL HILL (US) 2023-06-01 US disclosed
CN-115335043-A PGDH inhibitors and methods of making and using 迈欧伏特治疗公司 2022-11-11 CN disclosed
CN-115141220-A Aza-BODIPY compound and application thereof in-vivo tracing of nanoparticles 复旦大学 2022-10-04 CN disclosed
CN-109456205-B N-arylation method in aqueous phase system by using substituted quinoline or isoquinoline hydrazide pyridine-N-oxide as ligand 石河子大学 2021-09-21 CN disclosed
EP-3326715-B1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE CE PHARM CO LTD (CN) 2021-09-15 EP disclosed
EP-3326715-B1 OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE CE PHARM CO LTD (CN) 2021-09-15 EP disclosed
CN-106362797-B Oxalic acid amide ligand and application thereof in copper-catalyzed aryl halide coupling reaction 浙江中科创越药业有限公司 2021-05-28 CN disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2007013673-A1 FUSED HETEROCYCLES AS LCK INHIBITORS ASTELLAS PHARMA INC. (JP) 2007-02-01 WO disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed
CN-1229330-C N-arylating method using amino-acid as additives SHANGHAI INST ORGANIC CHEM (CN) 2005-11-30 CN disclosed
US-6911468-B2 Tyrosine phosphatase inhibitors TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-06-28 US disclosed
CN-1450049-A N-arylating method using amino-acid as additives SHANGHAI INST ORGANIC CHEM (CN) 2003-10-22 CN disclosed
US-20030144338-A1 Tyrosine phosphatase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-07-31 US disclosed
EP-1284260-A1 TYROSINE PHOSPHATASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 2003-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144338-A1 Tyrosine phosphatase inhibitors PTPRC, PTPN1, PTPRM MAPT 4800/4885KDM4E 171/4885ALDH1A1 2470/4885
US-20230167067-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES PPOX, AOC2, AOC3 MAPT 3005/4885KDM4E 766/4885ALDH1A1 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.